A Compendium of Clinical Research and Practice


Subscribe Current Issue Archives Continuing Education Submit an Article Contact Us
Search Articles:
Wounds Home
Current Issue
Archives
Search Articles
Subscribe to Wounds
Industry News
New Products
Classifieds
Continuing Education
Supplements
Enewsletters
Editorial Board
Contact Us
Author Instructions
Rapid Review
About Us

Bioengineered skin equivalent
Negative pressure wound therapy
Acellular dermal matrix
Diabetic neuropathy
Silver dressings
Enzymatic debridement

Autolytic debridement
Wound necrosis
Surgical debridement
Mechanical debridement
Wound fibroblasts
Delayed wound healing
Impaired wound healing
Compression stockings
Diabetic foot wounds
Pressure dressing
Wound Bed Preparation: The Science Behind the Removal of Barriers to Healing [PART 1]
Feature:
Wound Bed Preparation: The Science Behind the Removal of Barriers to Healing [PART 1]

- Stuart Enoch, MBBS, MRCSEd, MRCS (Eng);1 Keith Harding, MB ChB, MRCGP, FRCS2

Abstract: Wound healing involves a well-orchestrated, complex process leading to repair of injured tissues. However, chronic wounds do not follow the normal pattern of repair. This is due to underlying physiological problems associated with their development, which unless corrected would continue to cause wound deterioration. The key to effective wound care lies in a combination of three approaches: treatment of underlying medical problems, assessment and treatment of local wound bed, and effective management of any patient-centered concerns. An essential component of this recommended approach is restoration of healthy granulation tissue in the wound bed. Wound bed preparation brings a number of existing procedures, including debridement, treatment of infection, and management of exudate levels, together into a systematic approach to help restore the chronic wound bed environment. The aim of wound bed preparation is to remove the barriers to healing and initiate the repair process. This review explores the scientific rationale behind this concept and examines how wound bed preparation offers healthcare professionals an improved paradigm for the treatment of chronic wounds. By implementing wound bed preparation, the formation of healthy granulation tissue will be optimized and the efficiency of biotechnological therapies improved, which would ultimately reduce the time to wound closure.


[PART 1]

Introduction

Wound healing involves a complex series of events, which encompass chemotaxis, cell division, neovascularization, synthesis of new extracellular matrix (ECM) components, and the formation and remodeling of scar tissue. Soluble mediators, such as growth factors, cytokines, matrix metalloproteinases (MMPs), and their regulators, control many of the processes involved in wound healing via their effects on various cell types and the ECM.[1,2] In acute wounds, these processes, which are triggered by tissue injury, involve the four overlapping but well defined phases of hemostasis, inflammation, proliferation, and remodeling (Figure 1). Physiological events in a nonhealing wound, however, do not follow this traditional model of wound repair. The concept of wound bed preparation addresses this issue and provides a model that is appropriate for understanding and treating chronic wounds.

Figure 1
This flow chart illustrates the normal process of wound healing.


Normal Wound Healing

Vasoconstriction in combination with clot formation and platelet aggregation occurs in response to initial injury. Once aggregated, the platelets degranulate and release mediators that help form the fibrin clot together with growth factors and chemo-attractants. During this initial hemostatic phase, platelets release several growth factors, including platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and transforming growth factor-beta (TGF-b) into the wound bed. Neutrophils and macrophages migrate into the wound and secrete additional growth factors, such as transforming growth factor-alpha (TGF-a), heparin-binding epidermal growth factor (HB-EGF), and basic fibroblast growth factor (bFGF), which further stimulate the inflammatory process. These various growth factors are mitogenic and chemotactic for endothelial cells, macrophages, keratinocytes, and fibroblasts, which migrate to the site of the wound to form the “granulation tissue” or provisional matrix.[3]




During the earliest stages of repair, neutrophil proteases participate in antimicrobial defense and in the debridement of devitalized tissue at the wound site.[4] Macrophages, activated by CD4+ T helper cells and by the cytokine interferon-g (produced by T-lymphocytes and NK cells), stimulate acute inflammation through the secretion of cytokines, mainly tumor necrosis factor (TNF), IL-1 and chemokines, and short-lived lipid mediators, such as platelet-activating factor, prostaglandins, and leukotrienes. Their collective action is to further enhance local inflammation that is rich in neutrophils, which helps to phagocytose and destroy infectious organisms.[5] The cytokines play a further role in tissue repair: IL-1b stimulates the proliferation of fibroblasts, and TNF-a and IL-1b stimulate fibroblasts to synthesize MMPs.

Activated macrophages, along with neutrophils, remove dead tissues to facilitate repair after the infection is controlled. In addition, they induce the formation of repair tissue by secreting growth factors that stimulate fibroblast proliferation (PDGF), collagen synthesis (TGF-b), and new blood vessel formation (FGF). Though many different growth factors contribute in their own way to wound repair, FGF plays a pivotal role in this process, as it is a potent mitogen for endothelial cells, accelerates granulation tissue formation by increasing fibroblast proliferation and collagen accumulation,[6] and provides the initial angiogenic stimulus.[7]

Fibroblasts, epithelial cells, and vascular endothelial cells begin to multiply freely as the wound enters the proliferative phase of repair. During the proliferative phase, the number of inflammatory cells in the wound decreases, and fibroblasts, endothelial cells, and keratinocytes secrete further growth factors that are required to mediate the process of wound healing.

The development of granulation tissue during wound healing requires the formation of new capillaries. New vessel formation or sprouting of capillaries from pre-existing ones is called angiogenesis, and this plays a pivotal role in the complex process of wound healing. Angiogenesis is tightly regulated by factors that act by either stimulating or inhibiting vessel growth.[8] During wound healing, angiogenic capillary sprouts invade the fibrin/fibronectin-rich wound clot and within a few days organize into a microvascular network throughout the granulation tissue.[9] As collagen accumulates in the granulation tissue to produce scar, the density of blood vessels diminishes. Disturbance of this dynamic process may influence the development of chronic wounds.[10]

The rapid onset and predominance of proangiogenic factors optimizes healing in damaged tissues.[11] Among all proangiogenic factors, the one that has been extensively studied in wound vessel angiogenesis is the vascular endothelial growth factor (VEGF). Experimental evidence suggests that a defect in VEGF regulation might be associated with wound healing disorders,[12] and healing-impaired diabetic mice show decreased VEGF expression levels.[13] Initial angiogenic stimulus in wound healing might be provided by FGF-2, followed by a subsequent and more prolonged angiogenic stimulus mediated by VEGF.[7]

During the phases of inflammation and proliferation, proteolytic enzymes, such as MMPs and serine proteases, play an essential role in tissue repair and remodeling. Once in the tissue, the inflammatory cells and fibroblasts stimulate the production of MMP-1, -2, -3, and -9 so that they can degrade the damaged ECM in preparation for macrophage phagocytosis of the ECM debris. Cytokines, growth factors, and tissue inhibitors of metalloproteinases (TIMPs) tightly regulate the production and activity of MMPs.

The final phase of wound healing involves a balanced process that degrades old ECM and synthesizes new ECM in order to remodel the scar that was formed during proliferation and repair. Among the most important cells during this phase are the fibroblasts, as they synthesize matrix molecules, such as collagen, elastin, and proteoglycans. They also produce MMPs that degrade the matrix and TIMPs, which regulate the activity of MMPs. This phase can take several months and results in a mature scar.

In summary, normal wound healing is a complex and finely tuned process that is mediated by growth factors, cytokines including angiogenic mediators, and MMPs.[14] Although the phases involved in normal wound healing overlap, they occur in a timely manner and are tightly regulated.

The Chronic Wound

A chronic wound can be defined as a wound in which the normal process of healing has been disrupted at one or more points in the phases of hemostasis, inflammation, proliferation, and remodeling.[15] Chronic wounds have several distinctive features (Table 1) and in contrast to acute wounds, they fail to heal in a timely and orderly manner. Chronic wounds are often regarded as being “stuck” in the inflammatory or proliferative phases of wound healing. Since growth factors, cytokines, and proteases all play important roles in each phase of the wound healing process, alterations in one or more components of these factors may account for the impaired healing observed in chronic wounds. Analyses of the molecular and cellular environments of acute and chronic wounds have revealed several important
differences.




The cytokine environment of chronic wounds is substantially altered, and the levels of IL-1a, a pro-inflammatory cytokine, have been shown to be elevated in chronic wounds.[16] Trengove, et al.,[17] found that the levels of other pro-inflammatory cytokines (IL-1b and TNF-a), along with IL-1a, were significantly elevated (p = 0.01 for IL-1a, p = 0.005 for IL-1b, and p = 0.013 for TNF-a) in nonhealing wound fluids from leg ulcers compared to those from healing wounds. Moreover, the levels of these cytokines decreased substantially as the chronic wound healed, indicating a significant correlation between nonhealing wounds and increased levels of pro-inflammatory cytokines. They also found that there was a statistically significant (p = 0.002) decrease in the mitogenic activity in nonhealing wounds compared to healing wounds. Similarly, when chronic wound fluid is added to cultures of fibroblasts, keratinocytes, or vascular endothelial cells, it fails to stimulate DNA synthesis in these cells, which is in direct contrast to the DNA-synthesizing ability of acute wound fluid.[18,19]

Oxygen-derived free radicals have been implicated in the causation of venous ulceration and their persistence. Scavenging such radicals using antioxidants expedites healing of venous ulcers.[20] Nitric oxide (NO) is known to combine with hydroxyl free radicals forming peroxynitrate, a potent free radical, which causes tissue destruction. NO overexpression in chronic venous ulcers may be involved directly or indirectly (through production of peroxynitrate) in the pathogenesis and delayed healing of chronic venous ulcers through its effects on vasculature, inflammation, and collagen deposition.[21] In a study of 44 patients with chronic venous disease, Howlander and Coleridge Smith[22] observed that the total plasma NO levels were elevated in patients with severe skin damage. Similarly, Jude, et al.,[23] found that diabetic patients with recurrent neuropathic and neuroischemic foot ulcers had significantly higher plasma NO levels compared to patients with nonrecurrent foot ulcers (46.9 +/- 6.3 microm/L versus 30.2 +/-2.[4] microm/L respectively, p < 0.01).

Another important biochemical difference in chronic wounds is the level of protease activity, which is considerably higher than in acute wounds. In the phases of normal wound healing, the production and activity of proteases are tightly regulated, but this regulation appears to be disrupted in chronic wounds. For instance, the levels of various MMPs and serine proteases are markedly increased in fluids from chronic wounds. Levels of MMP-1, -2, and -9 have been shown to be elevated in fluid derived from pressure ulcers and venous leg ulcers compared with acute mastectomy wounds.[24,25] Furthermore, during granulation tissue formation in chronic pressure ulcers, data indicate a decrease in levels of MMPs and an increase in the levels of their inhibitors, TIMPs.[26] Other proteases, such as neutrophil elastase, were also observed to be significantly higher in chronic wounds.[27] Increased levels of serine proteases have been linked to the degradation of fibronectin, which is an essential protein involved in the remodeling of ECM and is necessary for granulation tissue formation during the remodeling phase. Moreover, in addition to being implicated in degrading essential ECM factors, in-vitro studies show that proteases in chronic wounds also degrade growth factors.[24,28]

A further aspect of chronic wounds that is distinct from acute wounds is the inability of cells to respond correctly to molecular regulators. Research has demonstrated that fibroblasts in skin ulcers that have failed to heal may not be as capable of responding to growth factors, such as PDGF and TGF.[29] Moreover, cells from venous ulcers that had been present for longer than three years grew more slowly, and some cells became senescent.[30,31]

The physiological implications of all these studies are that the altered molecular and cellular environment of chronic wounds contributes to the failure of these wounds to heal. This aberration of the healing process can compromise the overall anatomical and functional integrity of the wound. Moreover, most chronic wounds are complicated by an underlying physiological abnormality, such as diabetes, vascular insufficiency, or ischemia, which may contribute further to the failure of wound healing. The key to encouraging chronic wounds to heal more quickly is the rapid correction of the underlying physiological problems together with adequate preparation of the wound bed. The healing process of a chronic wound will be significantly hindered if the underlying pathology is not considered along with local barriers to healing.[32–34]

Wound Bed Preparation

Wound bed preparation extends the existing practice of using a holistic approach to evaluate and remove all barriers to healing, so that wound repair can progress normally. The overall goal of management is to achieve a stable wound that has healthy granulation tissue and one that is characterized by a well-vascularized wound bed. This would involve the removal of factors that delay healing.

Therefore, the way in which chronic wounds are viewed and managed should be based on a model that is both different from the acute wound paradigm and representative of the complex nature of nonhealing ulcers.[35] By generating such a model, the scientific understanding and clinical management of nonhealing wounds could be optimized. Because it is based on the clinical knowledge and physiology of nonhealing ulcers, wound bed preparation provides a model that is effective for the evaluation and treatment of chronic wounds.

Understanding and removing the barriers to healing will help to produce a wound bed with healthy granulation tissue that is ready for the next stage of repair.[32,36] The main barriers to healing in a chronic wound are necrotic tissue, bacterial imbalance, and altered exudate levels and composition. Wound bed preparation aims to remove these barriers to healing, and this is characterized by on-going debridement, reduction of bacterial burden, and effective exudate management. Since normal cellular and biochemical processes are disrupted in chronic wounds, a greater understanding of the wound microenvironment is essential in achieving a wound bed ready for the next stage of repair. The cellular and biochemical differences that occur in chronic wounds have been termed cellular dysfunction and biochemical imbalance, respectively, and constitute further barriers to healing.

This review aims to discuss each of the components of wound bed preparation with regard to science and practice and to explain how they can have a beneficial effect in the context of wound management. In addition, the various therapeutic options available at present to treat chronic wounds and the future treatment strategies are also tabulated in Table 2.




Necrotic Tissue and its Accumulation in Chronic Wounds

Necrotic tissue is dead tissue, which usually results from an inadequate local blood supply. Necrotic tissue contains dead cells and debris that are a consequence of the fragmentation of dying cells. Necrotic tissue changes color from red to brown or black/purple, as it becomes more dehydrated. Finally, it forms a black, dry, thick, and leathery structure known as eschar. This can be seen in a wide variety of wound types, including burns and all types of chronic wounds. In contrast, slough is a yellow fibrinous tissue that consists of fibrin, pus, and proteinaceous material. Slough can be found on the surface of a previously clean wound bed and it is thought to be associated with bacterial activity.[37] The accumulation of necrotic tissue or slough in a chronic wound is of major clinical significance, because it is thought to promote bacterial colonization and prevent complete repair of the wound.

Recently, the term necrotic burden has been proposed as an all-encompassing term to describe necrotic tissue, excess exudate, and high levels of bacteria present within dead tissue.[33] Due to the underlying pathogenic abnormalities in chronic wounds and the altered biochemical and cellular environment, necrotic tissue tends to continually accumulate.[33,38] However, it is not always feasible to fully remove the underlying pathogenic abnormality, making it even more essential to adequately prepare the wound bed. If the necrotic burden is allowed to accumulate in the chronic wound, it can prolong the inflammatory response, mechanically obstruct the process of wound contraction and impede reepithelization.[39]

Wound Debridement

Clinically, debridement has been used for many years to enhance wound closure. Steed and co-workers[40,41] have earlier highlighted its significance. The 1996 study compared rates of healing in patients with diabetic foot ulcers whose wounds were debrided using either topically applied growth factors (PDGF) alone or in combination with sharp debridement. The results showed that a lower rate of healing was observed in those centers that performed less frequent debridement. The authors concluded that debridement is a vital adjunct to topically applied growth factor therapy in the care of patients with chronic wounds.

Removal of necrotic tissue by debridement is beneficial for a number of reasons. Debridement removes dead, devitalized, or contaminated tissue, and any foreign material from a wound, which helps to reduce the number of microbes, toxins, and other substances that inhibit healing.[42–44] Foreign bodies, including soft necrotic tissue, bone fascia, nonviable muscle, and ligaments, have been shown to reduce host immune defenses and encourage active infection.[45,46]

There are five main methods of debridement: surgical or sharp, autolytic, enzymatic, mechanical, and biosurgery. The choice of debridement method will depend upon many factors, including the size, position, and type of wound, efficiency and selectivity of debridement method, pain management, exudate levels, risk of infection, and the cost of the procedure.[32] In some cases, it may be appropriate to use more than one method of debridement.

Surgical debridement. Surgical or sharp debridement is not a new technique, and historical texts show that ancient civilizations often made surgical changes to the wound bed.[47] Surgical debridement is the fastest way to remove dead tissue. It causes considerable pain, and hence, it was earlier restricted to the treatment of neuropathic diabetic ulcers where the use of anesthesia and pain management was not necessary. However, this problem could be overcome with the use of topically applied local anesthetics (e.g., combination of lidocaine [lignocaine] and prilocaine), applied 30 to 45 minutes prior to debridement.[48] Although surgical debridement is thought to be selective, there may be some damage to viable tissue, and bleeding is likely. Nevertheless, this may help to revitalize the wound and encourage healing by inundating the wound bed with growth factors and cytokines. Mild to moderate bleeding could be controlled by the application of pressure and a hemostatic calcium alginate dressing.

Autolytic debridement. All wounds experience some level of autolytic debridement, which is the natural and highly selective process by which endogenous proteolytic enzymes break down necrotic tissue. These endogenous enzymes are mainly produced by neutrophils and include elastase, collagenase, myeloperoxidase, acid hydrolase, and lysosomal enzymes.[49]

Autolytic debridement may not take place fast enough to encourage rapid wound healing and closure, but the use of occlusive dressings can enhance this natural process, while maintaining a moist wound bed and managing excess exudate.[50] This allows painless, selective debridement and promotes the formation of healthy granulation tissue.[51]

Autolytic debridement can result in the production of significant quantities of exudate. Typical practice for autolytic debridement involves the use of a hydrogel to soften and break down necrotic tissue covered with an absorptive, occlusive dressing to absorb the excess exudate.

With an increase in antibiotic-resistant pathogens, there has been a renaissance in recent times in the use of honey for the treatment of wounds and ulcers.[52] As well as having an antibacterial action, honey provides rapid autolytic debridement and deodorizes wounds, in addition to having anti-inflammatory properties[53] and stimulating immune responses.[54] Though the exact mode of action remains unclear, Tonks, et al.,[55] observed that reactive oxygen intermediate production was significantly decreased (p < 0.001), and TNF-a release was significantly enhanced (p < 0.001) by pasture honey and manuka honey.

Although on practical grounds, autolytic debridement is the easiest method of debriding wounds, it usually takes a prolonged period of time to achieve complete removal of necrotic tissue.

Enzymatic debridement. Enzymatic debridement is a highly selective method of wound debridement that uses naturally occurring proteolytic enzymes that are manufactured by the pharmaceutical and healthcare industry specifically for wound debridement. These exogenously applied enzymes work alongside the endogenous enzymes in the wound. Several enzyme debriding agents have been developed including bacterial collagenase, papain/urea, fibrinolysin/DNAse, trypsin, streptokinase-streptodornase combination, and subtilisin. Only the first three products are widely available commercially in those markets where they are registered, although availability varies geographically.

Collagenase-based debridement. Collagenase, derived from Clostridium histolyticum, is the best characterized of all of the enzyme debriding agents. It specifically digests all triple helical collagen and will not degrade any other proteins lacking the triple helix. This is a unique feature of bacterial collagenase, since none of the other available proteases can digest collagen.[56] It has been used for over 25 years and has a number of clinical advantages, including selectively removing dead tissue, being painless, and causing the least amount of blood loss.[57] This type of debridement can be appropriate to use in long-term care facilities and in the home care setting.[58] Clinical research has shown that bacterial collagenase is an effective and selective enzyme debriding agent in a range of wound types.[59–65]

Papain-based debridement. Papain is a nonspecific proteolytic enzyme derived from the fruit of the papaw tree (Carica papaya). Papain breaks down fibrinous material in necrotic tissue and requires the presence of sulfhydryl groups, such as cysteine, for its activity. It does not digest collagen,[66] and it requires specific activators that are present in necrotic tissue in order to be stimulated. Urea is combined with papain because urea is able to expose the activators of papain in necrotic tissue. Urea also denatures proteins, making them more susceptible to proteolysis by papain. The combination of papain and urea is approximately twice as effective at digesting protein compared with papain alone.[67] Papain use is known to produce an inflammatory response and possibly as a result of this, considerable pain is often experienced with the use of this method.[68,69] Therefore, chlorophyllin, an anti-agglutinin, has been added to preparations of papain/urea in an attempt to reduce the pain.[70,71] Current preparations containing the above combination tend to cause less pain. Papain/urea preparations, however, may be particularly useful in patients with pressure ulcers combined with a loss of sensation (e.g., spinal injuries), as pain may not be a limiting factor for its use in such instances.[33]

Mechanical debridement. Mechanical debridement is a nonselective, physical method of removing necrotic tissue and debris from a wound using mechanical force. This debridement method is generally easy to perform and is more rapid than autolytic and enzymatic debridement. However, this nonselective method can damage healthy granulation tissue both in the wound bed and at the margins of the wound thus causing significant discomfort to the patient. Despite these disadvantages, there are a number of mechanical debridement methods that are in use.

Wet-to-dry dressings are the simplest method of mechanical debridement, but due to the frequent dressing changes, it can require considerable nursing time and hence is costly.[72] Wet gauze dressings are placed onto the wound bed and allowed to dry, trapping the necrotic debris within the gauze. Upon removal of the dressing, embedded necrotic tissue and debris are mechanically separated from the wound bed.[73] Pressurized irrigation involves applying streams of water, delivered at either high or low pressure, to wash away bacteria, foreign matter, and necrotic tissue from the wound. However, if the pressure is too great, there may be a risk of forcing bacteria and debris deeper into the wound or damaging viable tissue.[74] Whirlpool therapy uses powered irrigation and can be very effective at loosening and removing surface wound debris, bacteria, necrotic tissue, and exudate from the wound. Ultrasound treatment has been used to remove necrotic tissue and has been shown to effectively debride wounds and reduce infection caused by bacteria.[75] Vacuum-assisted closure is a noninvasive form of mechanical or physical debridement that exposes the wound bed to negative pressure (approximately 125mmHg below ambient pressure) by way of a closed system. It helps healing of chronic wounds by minimizing exudate and slough in the wound bed, reducing tissue edema,[76,77] increasing peripheral blood flow, improving local oxygenation, and promoting angiogenesis and good quality granulation tissue.[78]

Biosurgery (myiasis). For a decade since its introduction in 1931, fly maggots have been known to help debride and heal wounds. This technique uses sterile maggots, which digest sloughy and necrotic material from the wound without damaging the surrounding healthy tissue.[37] In the study by Mumcuoglu, et al.,[79] complete debridement was achieved using maggots in 38 of the 43 patients (88%) with chronic leg ulcers and pressure ulcers. Among them, five patients had their limbs salvaged after being referred for amputation of the leg. Likewise, Sherman[80] in a cohort of 103 patients with pressure ulcers observed that 80 percent of maggot-treated wounds were completely debrided compared to only 48 percent of wounds that were treated by conventional therapy alone (p = 0.021). The precise mechanism by which maggots debride the wound and promote wound healing remains unclear. However, there is speculation that they probably act by ingesting and killing bacteria, exerting a bacteriostatic effect by increasing wound pH,[81] secreting proteolytic enzymes that are important in eschar degradation,[82] and increasing tissue oxygenation.[83] Nevertheless, despite recent encouraging reports,[80] some patients complain of increased pain with maggot therapy.[84] Likewise, the potential psychological and aesthetic considerations cannot be ignored.

Maintenance Debridement and Wound Bed Preparation

Traditionally, debridement has been undertaken as a single therapeutic step within defined time frames. This procedure is usually only repeated if necrotic tissue reappears, since it is assumed that healthy granulation tissue will form after complete debridement. Although this may be applicable for acute wounds, it is unlikely to remove the necrotic burden that continually accumulates in a chronic wound. In the case of nonhealing chronic wounds, it may be more appropriate to perform regular or even continuous debridement.

An important aspect of wound bed preparation is the recognition that chronic wounds have underlying pathogenic abnormalities that cause necrotic tissue to accumulate. Therefore, in order to facilitate wound progression, repeated removal of necrotic tissue will be necessary throughout the lifespan of the chronic wound. In this way an extended “maintenance” phase of debridement has been proposed.[33] This is more likely to be effective than a single intervention. Wound bed preparation advocates that clinicians should consider a steady state removal of the necrotic burden and that regular and efficient debridement is necessary to reduce necrotic burden and obtain healthy granulation tissue.[85]


References

1. Bennett NT, Schultz GS. Growth factors and wound healing: Biochemical properties of growth factors and their receptors. Am J Surg 1993a;165:728–37.
2. Bennett NT, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 1993b;166:74–81.
3. Martin P, Hopkinson-Woolley J, McCluskey J. Growth factors and cutaneous wound repair. Prog Growth Factor Res 1992;4:25–44.
4. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen 1999;7:433–41.
5. Abbas AK, Lichtman AH, Pober JS. Effector mechanisms of cell-mediated immunity. In: Abbas AK, Lichtman AH, Pober JS (eds). Cellular and Molecular Immunology, Fourth Edition. Philadelphia, PA: WB Saunders Company, 2000;(13):291–308.
6. Slavin J. Fibroblast growth factors: At the heart of angiogenesis. Cell Biol Int 1995;19:431–4.
7. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998;152(6):1445–52.
8. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–4.
9. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Invest Dermatol Symp Proc 2000;5(1):40–6.
10. Lauer G, Solberg S, Cole M, et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 2000;115(1):12–23.
11. Matthies AM, Low QE, Lingen MW, et al. Neuropilin-1 participates in wound angiogenesis. Am J Pathol 2002;160(1):289–96.
12. Altavilla D, Saitta A, Cucinotta D, et al. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001;50(3):667–74.
13. Di Peppe RS, Mangoni A, Zambruno MA, et al. Adenovirus-mediated VEGF (165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther 2002;9(19):1271–7.
14. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. In: Greenwald RA, Golub LM (eds). Inhibition of matrix metalloproteinases: Therapeutic potential. Ann NY Acad Sci 1994;732:51–64.
15. Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994;130(4):489–93.
16. Barone EJ, Yager DR, Pozez AL, et al. Interleukin-1 alpha and collagenase activity are elevated in chronic wounds. Plast Reconstr Surg 1998;102(4):1023–7.
17. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen 2000;8(1):13–25.
18. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen 1993;1:181–6.
19. Harris IR, Yee KC, Walters CE, et al. Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exper Dermatol 1995;4:342–9.
20. Salim AS. The role of oxygen-derived free radicals in the management of venous (varicose) ulceration: A new approach. World J Surg 1991;15(2):264–9.
21. Abd-El-Aleem SA, Ferguson MWJ, Appleton I, et al. Expression of nitric oxide synthase isoforms and arginase in normal human skin and chronic venous leg ulcers. J Pathol 2000;191(4):434–42.
22. Howlander MH, Coleridge Smith PD. Increased plasma total nitric oxide among patients with severe chronic venous disease. Int Angiol 2002;21(2):180–6.
23. Jude EB, Tentolouris N, Appleton I, et al. Role of neuropathy and plasma nitric oxide in recurrent neuropathic and neuroischemic diabetic foot ulcers. Wound Rep Regen 2001;9(5):353–9.
24. Yager DR, Zhang LY, Liang HX, et al. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996;107(5):743–8.
25. Schultz GS, Mast BA. Molecular analysis of the environment of healing and chronic wounds: Cytokines, proteases, and growth factors. WOUNDS 1998;10(6 Suppl):1F–9F.
26. Cook H, Davies KJ, Harding KG, Thomas DW. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol 2000;115:225–33.
27. Grinnell F, Zhu M. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J Invest Dermatol 1996;106(2):335–41.
28. Wlaschek M, Peus D, Achterberg V, et al. Protease inhibitors protect growth factor activity in chronic wounds. Br J Dermatol 1997;137(4):646.
29. Agren MS, Steenfos HH, Dabelsteen S, et al. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic leg ulcers is ulcer-age dependent. J Invest Dermatol 1999;112:463–9.
30. Mendez MV, Stanley AC, Park HY, et al. Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg 1998;28:876–83.
31. Mendez MV, Raffetto JD, Phillips T, et al. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg 1999;30:734–43.
32. Sibbald RG, Williamson D, Orsted HL, et al. Preparing the wound bed—debridement, bacterial balance, and moisture balance. Ost Wound Manag 2000a;46:14–35.
33. Falanga V. Wound bed preparation and the role of enzymes: A case for multiple actions of therapeutic agents. WOUNDS 2002;14(2):47–57.
34. Phillips TJ, al-Amoudi HO, Leverkus M, Park HY. Effect of chronic wound fluid on fibroblasts. J Wound Care 1998;7(10):527–32.
35. Grey JE, Harding KG. The chronic non-healing wound: How to make it better. Hosp Med 1998;59(7):557–63.
36. Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000a;8:347–52.
37. Thomas S. Sterile maggots and the preparation of the wound bed. In: Cherry GW, Harding KG, Ryan TJ (eds). Wound bed preparation. Proceedings of a symposium sponsored by the European Tissue Repair Society; 2000 Nov 24–25; Oxford UK. International Congress and Symposium Series 250. Royal Society of Medicine Press Limited, 2001:59–66.
38. Falabella AF, Carson P, Eaglstein WH, Falanga V. The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. J Am Acad Dermatol 1998;39:737–40.
39. Baharestani M. The clinical relevance of debridement. In: Baharestani M, Gottrup F, Holstein P, Vanscheidt W (eds). The Clinical Relevance of Debridement. Heidelberg: Springer-Verlag, 1999.
40. Steed DL. The diabetic ulcer study group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995;21:71–81.
41. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996;183:61–4.
42. Fowler E. Instrument/sharp debridement on non-viable tissue in wounds. Ost Wound Manag 1992;38:26, 28–30, 32–3.
43. Berger MM. Enzyme debriding preparations. Ost Wound Manag 1993;39:61–2, 66–9.
44. Fowler E, van Rijswijk L. Using wound debridement to help achieve the goals of care. Ost Wound Manag 1995;41(7A Suppl):23S–35S.
45. Elek S. Experimental staphylococcal infections in the skin of man. Ann NY Acd Sci 1956;69:56.
46. Edlich RF, Panek PH, Rodeheaver GT, et al. Physical and chemical configuration of sutures in the development of surgical infection. Ann Surg 1973;177:679–88.
47. Lyons AS, Petrucelli RJ. Medicine: An Illustrated History. New York, NY: Henry A. Abrams Publications, 1987.
48. Vanscheidt W, Sadjadi Z, Lillieborg S. EMLA anaesthetic cream for sharp leg ulcer debridement: A review of the clinical evidence for analgesic efficacy and tolerability. Eur J Dermatol 2001;11(2):90–6.
49. Sinclair RD, Ryan TJ. Types of chronic wounds: Indications for enzymatic debridement. In: Westerhof W, Vanscheidt W (eds). Proteolytic Enzymes and Wound Healing. New York, NY: Springer-Verlag, 1994:7–20.
50. Nemeth AJ, Eaglstein WH. Wound dressings and local treatment in leg ulcers: Diagnosis and treatment. In: Westerhof W (ed). Leg Ulcers: Diagnosis and Treatment. Amsterdam: Elsevier Science Publishers, 1993:325–33.
51. Eaglstein WH, Falanga V. Chronic wounds. Surg Clin North Am 1997;77:689–700.
52. Molan PC. Potential of honey in the treatment of wounds and burns. Am J Clin Dermatol 2001;2(1):13–9.
53. Molan PC. Re-introducing honey in the management of wounds and ulcers—theory and practice. Ost Wound Manag 2002;48(11):28–40.
54. Lusby PE, Coombes A, Wilkinson JM. Honey: A potent agent for wound healing? J WOCN 2002;29(6):295–300.
55. Tonks A, Cooper RA, Price AJ, et al. Stimulation of TNF-alpha release in monocytes by honey. Cytokine 2001;14(4):240–2.
56. Alteres WV. Debriding enzymes. J Enterostam Ther 1984;11:122–3.
57. Krane SM. Collagenases and collagen degradation. J Invest Dermatol 1982;79(Suppl 1):83S–86S.
58. Ziegler UE. Enzymatic debridement. In: Cherry GW, Harding KG, Ryan TJ (eds). Wound bed preparation. Proceedings of a symposium sponsored by the European Tissue Repair Society; 2000 Nov 24–25; Oxford UK. International Congress and Symposium Series 250. Royal Society of Medicine Press Limited, 2001:99–103.
59. Varma AO, Bugatch E, German FM. Debridement of dermal ulcers with collagenase. Surg Gynecol Obstet 1973;136(2):281–2.
60. Barrett D, Klibanski A. Collagenase debridement. Am J Nurs 1973;73(5):849–51.
61. Vrabec R, Moserova J, Konickova Z, et al. Clinical experience with enzymatic debridement of burned skin with the use of collagenase. J Hyg Epidemiol Microbiol Immunol 1974;18(4):496–8.
62. Zaruba F, Lettl A, Brozkova L, et al. Collagenase in the treatment of ulcers in dermatology. J Hyg Epidemiol Microbiol Immunol 1974;18(4):499–500.
63. Vetra H, Whittaker D. Hydrotherapy and topical collagenase for decubitus ulcers. Geriatrics 1975;30:53–8.
64. Rao DB, Sane PG, Georgiev EL. Collagenase in the treatment of dermal and decubitus ulcers. J Am Geriatr Soc 1975;23:22–30.
65. Altman MI, Goldstein L, Horowitz S. Collagenase: An adjunct to healing trophic ulcerations in the diabetic patient. J Am Podiatry Assoc 1978;68(1):11–5.
66. Shapira E, Giladi A, Neuman Z. Use of water insoluble papain (WIP) for debridement of burn eschar and necrotic tissue. Plast Reconstr Surg 1973;52:279–81.
67. Silverstein P, Ruzicka FJ, Helmkamp GM, et al. In vitro evaluations of enzymatic debridement of burn eschar. Surgery 1973;73:15–22.
68. Curtis R, Blache C, Johnston K, et al. Accuzyme papain urea ointment versus collagenase Santyl ointment in the treatment of partial thickness burn wounds. Proceedings: Am Burn Assoc Meeting, 1999.
69. Rutkowski ER, Lozano DD, Hansbrough JF. A comparison of the debridement of full thickness burns in mice treated with collagenase versus papain-urea ointment. Proceedings: Wound Healing Society meeting, 1999.
70. Miller EW. Decubitus ulcers treated with papain-urea-chlorophyllin ointment. NY State Med 1956;1446–8.
71. Miller JM, Howard F. The interaction of papain, urea, and water-soluble chlorophyll in a proteolytic ointment for infected wounds. Surgery 1958;43:939–48.
72. Mosher BA, Cuddigan J, Thomas DR, Boudreau DM. Outcomes of 4 methods of debridement using a decision analysis methodology. Adv Wound Care 1999;12(2):81–8.
73. Hulten L. Dressings for surgical wounds. Am J Surg 1994;167(1A):42S–44S.
74. Dow G, Browne A, Sibbald RG. Infection in chronic wounds: Controversies in diagnosis and treatment. Ost Wound Manag 1999;45:23–40.
75. Kloth LC, McCulloch JM. Promotion of wound healing with electrical stimulation. Adv Wound Care 1996;9(5):42–5.
76. DeFranzo AJ, Argenta LC, Marks MW, et al. The use of vacuum-assisted closure therapy for the treatment of lower-extremity wounds with exposed bone. Plast Reconstr Surg 2001;108(5):1184–91.
77. Webb LX. New techniques in wound management: Vacuum-assisted wound closure. J Am Acad Orthop Surg 2002;10(5):303–11.
78. Voinchet V, Magalon G. Vacuum assisted closure. Wound healing by negative pressure. Ann Chir Plast Esthet 1996;41(5):583–9.
79. Mumcuoglu KY, Ingber A, Gilead L, et al. Maggot therapy for the treatment of intractable wounds. Int J Dermatol 1999;38(8):623–7.
80. Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure ulcers. Wound Repair Regen 2002;10(4):208–14.
81. Thomas S, Andrews A. The use of larval therapy in wound management. J Wound Care 1998;7:521–4.
82. Vistnes LM, Lee R, Ksander GA. Proteolytic activity of blowfly larvae secretions in experimental burns. Surgery 1981;90:835–41.
83. Wollina U, Liebold K, Schmidt WD, et al. Biosurgery supports granulation and debridement in chronic wounds—clinical data and remittance spectroscopy measurement. Int J Dermatol 2002;41(10):635–9.
84. Mumcuoglu KY. Clinical applications for maggots in wound care. Am J Clin Dermatol 2001;2(4):219–27.
85. Falanga V. Introducing the concept of wound bed preparation. International Forum on Wound Care 2001;16(1):1–4.
86. Kerstein MD. Wound infection: Assessment and management. WOUNDS 1996;8:141–4.
87. De Haan B, Ellis H, Wilks M. The role of infection in wound healing. Surg Gynecol Obstet 1974;138:693–700.
88. Pollack SV. The wound healing process. Clin Dermatol 1984;2:8–16.
89. Marks J, Harding KG, Hughes LE. Staphylococcal infection of open granulating wounds. Br J Surg 1987;74(2):95–7.
90. Madsen SM, Westh H, Danielsen L, Rosdahl VT. Bacterial colonisation and healing of venous leg ulcers. APMIS 1996;104:895–9.
91. Cutting KF, Harding KG. Criteria for identifying wound infection. J Wound Care 1994;3(4):198–201.
92. Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized wound infection. Wound Repair Regen 2001;9(3):178–86.
93. Krizek T, Robson M, Kho E. Bacterial growth in skin graft survival. Surg Forum 1967;18:518.
94. Robson MC, Lea CE, Dalton JB, Heggers JP. Quantitative bacteriology and delayed wound closure. Surg Forum 1968;19:501–2.
95. Thomson PD. Immunology, microbiology, and the recalcitrant wound. Ost Wound Manag 2000;46(Suppl 1A): 77S–82S.
96. Robson M, Duke W, Krizek T. Rapid bacterial screening in the treatment of civilian wounds. J Surg Res 1973;14:420.
97. Robson MC, Heggers JP. Surgical infection II: The beta-hemolytic streptococcus. J Surg Res 1969;9:289–92.
98. Bucknall TE. The effect of local infection upon wound healing: An experimental study. Br J Surg 1980;67:851–5.
99. Thomson PD. What is the role of bacteria in chronic wound exudates? In: Cherry G, Harding KG (eds). Management of wound exudate. Proceedings of a joint meeting of the European Wound Management Association and the European Tissue Repair Society. London, England. Churchill Communications Limited, 1997:35–8.
100. Facklam R, Washington J. Streptococcus and elated catalase-negative gram-positive cocci. In: Balows A, Hausler W, Hermann K, et al. (eds). Manual of Clinical Microbiology, Fifth Edition. Washington, DC: American Society for Microbiology, 1991:238.
101. Bohnen J, Matlow A, Nohr C, et al. Pathogenicity of enterococcus in a rat model of fecal peritonitis. In: Program and abstracts of the Interscience Conference Antimicrobial Agents Chemotherapy, 1993. Abstract 276.
102. Schuchat A. Group B streptococcus. Lancet 1999;353:51.
103. Davies CE, Wilson MJ, Harding KG, et al. Use of molecular techniques to study microbial diversity in the skin: Chronic wounds reevaluated. Wound Rep Reg 2001;9:332–40.
104. Deresinski S. Infections in the diabetic patient: Strategies for the clinician. Infectious Disease reports. 1995;1:1.
105. Davey ME, O’Toole GA. Microbial biofilms: From ecology and molecular genetics. Microbiol Mol Biol Rev 2000;64:847–67.
106. Laato M, Niinikoski J, Lundberg C, Gerdin B. Inflammatory reaction in blood flow and experimental wounds inoculated with Staphylococcus aureus. Eur Surg Res 1988;20:33–8.
107. Filius PM, Gyssens IC. Impact of increasing antimicrobial resistance on wound management. Am J Clin Dermatol 2002;3(1):1–7.
108. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001;14:244–69.
109. Moore K, Thomas A, Harding KG. Iodine released from the wound dressing Iodosorb modulates the secretion of cytokines by human macrophages responding to bacterial lipopolysaccharide. Int J Biochem Cell Biol 1997;29(1):163–71.
110. Sundberg J, Meller R. A retrospective review of the use of cadexomer iodine in the treatment of chronic wounds. WOUNDS 1997;9:68–86.
111. Moberg S, Hoffman L, Grennert M, Holst A. A randomized trial of cadexomer iodine in decubitus ulcers. J Am Geriatr Soc 1983;31:462–5.
112. Gruber RP, Vistnes L, Pardoe R. The effect of commonly used antiseptics on wound healing. Plast Reconstr Surg 1975;55:472–6.
113. Viljanto J. Disinfection of surgical wounds without inhibition of normal wound healing. Arch Surg 1980;115:253–6.
114. Rodeheaver G, Bellamy W, Kody M, et al. Bactericidal activity and toxicity of iodine-containing solutions in wounds. Arch Surg 1982;117:181–6.
115. Hermans RP. Topical treatment of serious infections with special reference to use of a mixture of silver sulfadiazine and cerium nitrate: Two clinical studies. Burns Incl Therm Inj 1984;11:59–62.
116. Robins P, Day C, Lew R. A multivariate analysis of factors affecting wound healing time. J Dermatol Surg Oncol 1984;10:219–21.
117. Niedner R, Schopf E. Inhibition of wound healing by antiseptics. Br J Dermatol 1986;115(Suppl 31):41–4.
118. Danielsen L, Cherry GW, Harding K, Rollman O. Cadexomer iodine in ulcers colonised by Pseudomonas aeruginosa. J Wound Care 1997;6(4):169–72.
119. Mertz PM, Davis SC, Brewer L, et al. Can antimicrobials be effective without impairing wound healing? The evaluation of cadexomer iodine ointment. WOUNDS 1994;6:184–93.
120. Mertz PM, Oliveira-Gandia MF, Davis SC. The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg 1999;25:89–93.
121. Cooper ML, Laxer JA, Hansbrough JF. The cytotoxic effects of commonly used topical anti-microbial agents on human fibroblasts and keratinocytes. J Trauma 1991;31(6):775–84.
122. Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. Arch Surg 1985;120(3):267–70.
123. Fleischer W, Reimer K. Povidone-iodine in antisepsis: State of the art. Dermatology 1997;195(Suppl 2):3–9.
124. Drosou A, Falabella A, Kirsner R. Antiseptics on wounds: An area of controversy. WOUNDS 2003;15(5):149–66.
125. Sibbald RG, Coutts P, Browne AC, Coehlo S. Acticoat, a new ionized silver-coating dressings: Its effect on bacterial load and healing rates. Poster presented at: First World Wound Healing Congress, September 10–13, 2000b; Melbourne, Australia.
126. Wright JB, Hansen DL, Burrell RE. The comparative efficacy of two controlled release silver dressings. WOUNDS 1998;10(6):179–88.
127. Bishop JB, Philips LG, Mustoe TA, et al. A prospective randomised evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg 1992;16(2):251–7.
128. Kucan JO, Robson MC, Heggers JP, et al. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. J Am Geriatr Soc 1981;29(5):232–5.
129. Mi FL, Wu YB, Shyu SS, et al. Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. J Biomed Mater Res 2002;59(3):438–49.
130. Dhingra U, Schauerhammer RR, Wangensteen OW. Peripheral dissemination of bacteria in contaminated wounds; role of devitalised tissue: Evaluation of therapeutic measures. Surgery 1976;80(5):535–43.
131. Sapico FL, Canawati HN, Witte JL, et al. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. J Clin Microbiol 1980;12:413–20.
132. Rosner K, Ross C, Karlsmark T, et al. Immunohistochemical characterization of the cutaneous cellular infiltrate in different areas of chronic leg ulcers. APMIS 1995;103(4):293–9.
133. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen 1996;4:321–5.
134. Falanga V, Grinnell F, Gilchrest B, et al. Workshop on the pathogenesis of chronic wounds. J Invest Dermatol 1994;102:125–7.
135. Katz MH, Alvarez AF, Kirsner RS, et al. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol 1991;25:1054–8.
136. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996;4:411–20.
137. Weckroth M, Vaheri A, Lauharanta J, et al. Matrix metalloproteinases, gelatinise and collagenase, in chronic leg ulcers. J Invest Dermatol 1996;106:1119–24.
138. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993;101:64–8.
139. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Repair Regen 1999;7:442–52.
140. Drinkwater SL, Smith A, Sawyer BM, Burnard KG. Effect of venous ulcer exudates on angiogenesis in vitro. Br J Surg 2002;89(6):709–15.
141. Staiano-Coico L, Higgins PJ, Schwartz SB, et al. Wound fluids: A reflection of the state of healing. Ost Wound Manag 2000;46(Suppl 1A):85S–93S.
142. Thomas DW, O’Neill ID, Harding KG, et al. Cutaneous wound healing—a current perspective. J Oral Maxillofac Surg 1995;53:442–7.
143. Grinnell F, Ho CH, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: Analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol 1992;98(4):410–6.
144. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res 1998;290(Suppl):S47–54.
145. Agren MS, Eaglstein WH, Ferguson MW, et al. Causes and effects of the chronic inflammation in venous leg ulcers. Acta Derm Venereol (Stockh) 2000;210(Suppl):3–17.
146. Stanley AC, Park HY, Phillips TJ, et al. Reduced growth of dermal fibroblasts from chronic leg ulcers can be stimulated with growth factors. J Vasc Surg 1997;26:994–1001.
147. Campisi J. Replicative senescence: An old lives’ tale? Cell 1996;84:497–500.
148. Vande Berg JS, Rudolph R, Hollan C, Haywood-Reid PL. Fibroblast senescence in pressure ulcers. Wound Repair Regen 1998;6:38–49.
149. Hasan A, Murata H, Falabella A, et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci 1997;16:59–66.

Wounds - ISSN: 1044-7946 - Volume 15 - Issue 7 - July 2003 - Pages: 213 - 229



Supplements:

Special Publication:
The following is a collection of publications from Healthpoint intended to facilitate expeditious, cost-effective wound care management. There will be nine publications total.

Related Links:
Symposium on Advanced Wound Care (SAWC)
The Buck Stops Here
Association of Advanced Wound Care
Ostomy/Wound Management
Podiatry Today
Vascular Disease Management
Wound Healing Society

Article Submission:
All submissions for consideration should be submitted online using the Rapid Review Web-Based Review System at www.rapidreview.com. Authors should scroll down to HMP Communications and click on Author.


© 2008 HMP Communications | All Rights Reserved
83 General Warren Blvd | Suite 100 | Malvern, PA 19355